The Government announced a Sector Deal with the life sciences sector today, which details investment by 25 organisations from across the sector that aims to ensure the next wave of breakthrough treatments, innovative medical research and technologies, and high skilled jobs are created in Britain. With a particular focus on research, genomics and clinical trials, the Deal sets out agreed strategic goals for industry, academia and the Government.

Sarah Haywood, CEO at MedCity, responds to the announcement:

“The UK is one of the best places in the world for cutting-edge science and this boost of investment from some of the biggest names in Pharma ensures we continue to be at the forefront of innovative research, technologies and treatments.

“It’s great to see the confidence in The Golden Triangle with a new collaboration between J&J and Oxford University for mental health clinical trials; GSK’s £40m investment into genetic research at its global centre in Stevenage; MSD’s new research hub in London; and AstraZeneca’s £500m global HQ at Cambridge Biomedical Campus coming up next year.

“The Deals will also strengthen the UK’s genomics industry including a new partnership between GSK, AstraZeneca and the Government to contribute to the whole genome sequencing of the UK Biobank, which builds on the work of innovative companies such as Cambridge Epigenetix, Genomics plc and Congenica with Genomics England.

“Today’s announcements are a great start towards Government, industry and academia coming together to deliver long-term investment into the life sciences sector and MedCity is keen to work with these players to help them grow their business in the region.”

If you have any questions, please get in touch with Kim Watson, Communications Manager at MedCity, at or call +44 (0) 7553 374546.